Alterity Therapeutics Secures Key US Patent for Lead Asset
Alterity Therapeutics secured a USPTO patent for ATH434, extending market protection for its neurodegenerative drug candidate to 2045.
Alterity got official permission from the US government to be the only company selling its brain-disease medicine ATH434 until 2045. This is like getting a long-term lock on a store shelf, which gives the company more time to make money if the drug works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.